Q2 profit falls 47%, but H1 revenue rises 35.6%

Order pipeline disclosedInvestor Communications View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹19430.00

prior close

₹18501.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+2.0%-1.0% vs market

Pharmaceuticals peers, median of 173sector+0.8%+0.2% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.5

10m

+6.3

15m

+6.6

30m

+5.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+2.0-1.0+0.8+0.2

Next day

+1.9+2.8-0.9+1.6+0.3

+1.4pendingpending+1.5-0.1

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue fell 11.4% to ₹457.2 crore. Operating profit before interest, tax, depreciation and amortisation declined 33.4% to ₹104.6 crore, with margin falling to 22.9% from 30.4%; profit after tax dropped 47% to ₹51.1 crore. H1 revenue rose 35.6% to ₹1,107.2 crore and profit after tax rose 80.2% to ₹198.5 crore. Management retained its FY27 and following-year growth outlook, citing commercial products and new orders.

Likely market impact

Q2 profit fall and margin compression may pressure the stock near term; H1 growth, ₹208 crore net cash and pipeline progress support the outlook.